Dyadic International, Inc. (DYAI)

NCM – Real Time Price. Currency in USD

0.72

+0.01 (0.79%)

At close: May 12, 2026, 4:00 PM EDT

0.71

-0.01 (-1.65%)

Pre-market: May 13, 2026, 7:27 AM EDT

29.04.2026

Dyadic to Report Q1 2026 Financial Results and Host Conference Call on Wednesday May 13, 2026

JUPITER, Fla., April 29, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. d/b/a Dyadic Applied BioSolutions ("Dyadic", "we", "us", "our", or the "Company") (Nasdaq: DYAI), a global biotechnology company focused on the scalable production of high-value, precision engineered functional input proteins for use in life sciences, food and nutrition, and industrial biotechnology applications utilizing its proprietary gene expression platforms, today announced that it will report its financial results for the quarter ended March 31, 2026 and host a corporate update conference call on Wednesday, May 13, 2026.

26.03.2026

Dyadic International, Inc. (DYAI) Q4 2025 Earnings Call Transcript

25.03.2026

Dyadic Announces 2025 Financial Results and Highlights Recent Company Progress

Commercial launch of AlbuFree™ DX recombinant human albumin by Proliant Health & Biologicals using Dyadic's production platform, with Dyadic eligible to receive a share of profits from product sales Expanded strategic collaboration with Fermbox Bio, including the launch of animal-origin-free recombinant DNase I (RNase-free) as the first commercialized product under the expanded partnership Signed an OEM distribution agreement with IBT Bioservices to commercialize Dyadic's recombinant DNase I and transferrin for research and cell culture applications through IBT's global distribution channels Entered a development and commercialization agreement with BRIG Bio to produce animal-free bovine alpha-lactalbumin for global nutrition markets, which includes funded development, milestones, and potential revenue participation Inzymes announced plans to commercialize recombinant non-animal bovine chymosin in 2026 after meeting development milestones and making an additional milestone payment to Dyadic Cash, cash equivalents, restricted cash and investment grade securities of $8.6 million as of December 31, 2025 Dyadic to host an earnings call at 5:00 pm ET JUPITER, Fla., March 25, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), d/b/a, Dyadic Applied BioSolutions, a global biotechnology company producing precision-engineered, animal-free proteins and enzymes for diverse commercial applications, today reported its financial results for 2025 along with significant corporate achievements.

16.03.2026

Dyadic Applied BioSolutions Announces Commercial Distribution Partnership with IBT Bioservices

JUPITER, Fla., March 16, 2026 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company producing precision-engineered, animal-free proteins and enzymes for life science, food and nutrition, and bioindustrial applications today announced that it has entered into an original equipment manufacturer (“OEM”) distribution agreement with Integrated Biotherapeutics, LLC, d/b/a IBT Bioservices (“IBT”), a life sciences reagent manufacturer and distributor serving global research markets.

11.03.2026

Dyadic to Report 2025 Full Year Financial Results and Host Conference Call on Wednesday, March 25, 2026

JUPITER, Fla., March 11, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. d/b/a Dyadic Applied BioSolutions ("Dyadic", "we", "us", "our", or the "Company") (Nasdaq: DYAI), a global biotechnology company focused on the scalable production of high-value, precision engineered functional input proteins for use in life sciences, food and nutrition, and industrial biotechnology applications utilizing its proprietary gene expression platforms, today announced that it will report its financial results for the year ended December 31, 2025 and host a corporate update conference call on Wednesday, March 25, 2026.

04.03.2026

Dyadic and Fermbox Bio Launch First Product Under Expanded Collaboration: Animal-Origin-Free Recombinant DNase I (RNase-Free)

JUPITER, Fla. and BENGALURU, India, March 04, 2026 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company producing precision-engineered, animal-free proteins and enzymes for life science, food and nutrition, and bio-industrial uses, and Fermbox Bio (“Fermbox”), a biotech research and manufacturing company developing sustainable bio-based products through precision fermentation and advanced biotechnology tools, today announced the commercial launch of animal-origin-free Recombinant DNase I (RNase-free).

02.03.2026

Dyadic Applied BioSolutions and Inzymes ApS Announce Planned 2026 Commercialization of Non-Animal Dairy Enzyme Following Achievement of Development Milestone

Dyadic Applied BioSolutions and Inzymes ApS Announce Planned 2026 Commercialization of Non-Animal Dairy Enzyme Following Achievement of Development Milesto

Videos

No Data

There is no data to display

Press releases

25.03.2026

Dyadic Announces 2025 Financial Results and Highlights Recent Company Progress

16.03.2026

Dyadic Applied BioSolutions Announces Commercial Distribution Partnership with IBT Bioservices

04.03.2026

Dyadic and Fermbox Bio Launch First Product Under Expanded Collaboration: Animal-Origin-Free Recombinant DNase I (RNase-Free)

02.03.2026

Dyadic Applied BioSolutions and Inzymes ApS Announce Planned 2026 Commercialization of Non-Animal Dairy Enzyme Following Achievement of Development Milestone

Dyadic Applied BioSolutions and Inzymes ApS Announce Planned 2026 Commercialization of Non-Animal Dairy Enzyme Following Achievement of Development Milesto

Dyadic International, Inc. (DYAI)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Dyadic International, Inc. (DYAI)

Dyadic to Report Q1 2026 Financial Results and Host Conference Call on Wednesday May 13, 2026

Dyadic International, Inc. (DYAI) Q4 2025 Earnings Call Transcript

Dyadic Announces 2025 Financial Results and Highlights Recent Company Progress

Dyadic Applied BioSolutions Announces Commercial Distribution Partnership with IBT Bioservices

Dyadic to Report 2025 Full Year Financial Results and Host Conference Call on Wednesday, March 25, 2026

Dyadic and Fermbox Bio Launch First Product Under Expanded Collaboration: Animal-Origin-Free Recombinant DNase I (RNase-Free)

Dyadic Applied BioSolutions and Inzymes ApS Announce Planned 2026 Commercialization of Non-Animal Dairy Enzyme Following Achievement of Development Milestone

Videos

No Data

Press releases

Dyadic Announces 2025 Financial Results and Highlights Recent Company Progress

Dyadic Applied BioSolutions Announces Commercial Distribution Partnership with IBT Bioservices

Dyadic and Fermbox Bio Launch First Product Under Expanded Collaboration: Animal-Origin-Free Recombinant DNase I (RNase-Free)

Dyadic Applied BioSolutions and Inzymes ApS Announce Planned 2026 Commercialization of Non-Animal Dairy Enzyme Following Achievement of Development Milestone

Dyadic to Report Q1 2026 Financial Results and Host Conference Call on Wednesday May 13, 2026

Dyadic International, Inc. (DYAI) Q4 2025 Earnings Call Transcript

Dyadic Announces 2025 Financial Results and Highlights Recent Company Progress

Dyadic Applied BioSolutions Announces Commercial Distribution Partnership with IBT Bioservices

Dyadic to Report 2025 Full Year Financial Results and Host Conference Call on Wednesday, March 25, 2026

Dyadic and Fermbox Bio Launch First Product Under Expanded Collaboration: Animal-Origin-Free Recombinant DNase I (RNase-Free)

Dyadic Applied BioSolutions and Inzymes ApS Announce Planned 2026 Commercialization of Non-Animal Dairy Enzyme Following Achievement of Development Milestone

Videos

No Data

Press releases

Dyadic Announces 2025 Financial Results and Highlights Recent Company Progress

Dyadic Applied BioSolutions Announces Commercial Distribution Partnership with IBT Bioservices

Dyadic and Fermbox Bio Launch First Product Under Expanded Collaboration: Animal-Origin-Free Recombinant DNase I (RNase-Free)

Dyadic Applied BioSolutions and Inzymes ApS Announce Planned 2026 Commercialization of Non-Animal Dairy Enzyme Following Achievement of Development Milestone

Search stocks

Dyadic International, Inc. (DYAI)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Dyadic International, Inc. (DYAI)

Dyadic to Report Q1 2026 Financial Results and Host Conference Call on Wednesday May 13, 2026

Dyadic International, Inc. (DYAI) Q4 2025 Earnings Call Transcript

Dyadic Announces 2025 Financial Results and Highlights Recent Company Progress

Dyadic Applied BioSolutions Announces Commercial Distribution Partnership with IBT Bioservices

Dyadic to Report 2025 Full Year Financial Results and Host Conference Call on Wednesday, March 25, 2026

Dyadic and Fermbox Bio Launch First Product Under Expanded Collaboration: Animal-Origin-Free Recombinant DNase I (RNase-Free)

Dyadic Applied BioSolutions and Inzymes ApS Announce Planned 2026 Commercialization of Non-Animal Dairy Enzyme Following Achievement of Development Milestone

Videos

No Data

Press releases

Dyadic Announces 2025 Financial Results and Highlights Recent Company Progress

Dyadic Applied BioSolutions Announces Commercial Distribution Partnership with IBT Bioservices

Dyadic and Fermbox Bio Launch First Product Under Expanded Collaboration: Animal-Origin-Free Recombinant DNase I (RNase-Free)

Dyadic Applied BioSolutions and Inzymes ApS Announce Planned 2026 Commercialization of Non-Animal Dairy Enzyme Following Achievement of Development Milestone

Dyadic to Report Q1 2026 Financial Results and Host Conference Call on Wednesday May 13, 2026

Dyadic International, Inc. (DYAI) Q4 2025 Earnings Call Transcript

Dyadic Announces 2025 Financial Results and Highlights Recent Company Progress

Dyadic Applied BioSolutions Announces Commercial Distribution Partnership with IBT Bioservices

Dyadic to Report 2025 Full Year Financial Results and Host Conference Call on Wednesday, March 25, 2026

Dyadic and Fermbox Bio Launch First Product Under Expanded Collaboration: Animal-Origin-Free Recombinant DNase I (RNase-Free)

Dyadic Applied BioSolutions and Inzymes ApS Announce Planned 2026 Commercialization of Non-Animal Dairy Enzyme Following Achievement of Development Milestone

Videos

No Data

Press releases

Dyadic Announces 2025 Financial Results and Highlights Recent Company Progress

Dyadic Applied BioSolutions Announces Commercial Distribution Partnership with IBT Bioservices

Dyadic and Fermbox Bio Launch First Product Under Expanded Collaboration: Animal-Origin-Free Recombinant DNase I (RNase-Free)

Dyadic Applied BioSolutions and Inzymes ApS Announce Planned 2026 Commercialization of Non-Animal Dairy Enzyme Following Achievement of Development Milestone